Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer

Abstract

Background: A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors. However, the relationship between the expression of the mucin-type sialyl-Tn antigen (sTn) and PD-L1 remains unclear in breast cancer (BC).Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues. Methods: We retrospectively analyzed the clinical data of 380 invasive BC patients between January 2011 and January 2014. The last follow-up time was January 31, 2019 with a median follow-up of 62 months. The expression of the sTn antigen and PD-L1 in 380 tumor specimens was assessed by immunohistochemistry. Correlations between sTn/PD-L1 expression and clinicopathological features and prognoses were analyzed. Results: In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%). Pearson's contingency analysis showed that sTn and PD-L1 expression in tumor tissues demonstrated a high correlation (P<0.001). High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumorinfiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002). Moreover, patients with concomitant high expression of both markers had the highest risk of relapse (P<0.001) and mortality (P<0.001). The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941,

Bioinformatic analysis reveals prognostic value and immunotherapy potential of Siglec-15 in laryngeal squamous cell carcinoma

“…Normally, Siglec-15 is weakly expressed in macrophage. However, M-CSF (Macrophage Colony-Stimulating Factor) induces the appearance of Siglec-15 in tumor-associated macrophages in response to tumor or inflammatory factor stimulation, remodeling the tumor microenvironment and promoting tumor metastasis and poor prognosis [ 33 , 34 ]. Macrophages are an important component of TME immune cells that promote tumorigenesis, progression, metastasis and have acquired a lot of interest as potential therapeutic targets [ 35 ].…”

Bittersweet Sugars: How Unusual Glycan Structures May Connect Epithelial-to-Mesenchymal Transition and Multidrug Resistance in Cancer

“…A more recent study has shown that hypersialylated cancer cells increase siglec-7 and sigle-9 signaling, driving macrophage differentiation to an immunosuppressive phenotype, further supporting the notion that glycoconjugates can modulate immune checkpoints [ 34 ]. Additionally, a retrospective study on breast cancer patients showed that patients exhibiting a high STn/PD-L1 profile had poorer prognoses and might benefit from therapeutic strategies focusing on both fronts [ 35 ].…”

Role of Truncated O-GalNAc Glycans in Cancer Progression and Metastasis in Endocrine Cancers

“…Breast cancer Tn (57-92%), STn (33-42%), T (32%) [87,[108][109][110] Gastric cancer STn (50-78%), Tn (92%), T (20%) [111,112] Colorectal cancer Tn (51-98%), STn (75-87%), T (20%) [87,113,114] Lung cancer Tn (16%), STn (33%), T (10%) [87] Pancreatic cancer Tn (53%), STn (56-97%), T (16-48%) [87,115] Skin cancer Tn (33-50%), STn (24%), T (25%) [87,116] Brain cancer Tn (51%), STn (80%), T (20%) [87] Mesenchymal cancers No expression [87]…”